H DL (high-density lipoprotein) cholesterol levels are inversely correlated with coronary heart disease in epidemiological studies 1 ; however, whether high HDL directly lowers atherosclerotic disease in humans has been questioned by recent drug trials and a Mendelian randomization study. 2, 3 Nevertheless, raising HDL levels in mice via overexpression of human apoA1 (apolipoprotein A1) has consistently reduced atherosclerosis in mouse models. 4, 5 The antiatherogenic property of HDL is partly attributed to its role in reverse cholesterol transport. This pathway starts with apoA1 interacting with cellular ABCA1 (ATP-binding cassette protein A1) to assemble cellular free cholesterol and phospholipids to form nascent HDL (nHDL). We have shown that ABCA1 mediates the unfolding of apoA1's N-terminal helical hairpin 6 and proposed a model for the mechanism of ABCA1-mediated nHDL assembly.
H DL (high-density lipoprotein) cholesterol levels are inversely correlated with coronary heart disease in epidemiological studies 1 ; however, whether high HDL directly lowers atherosclerotic disease in humans has been questioned by recent drug trials and a Mendelian randomization study. 2, 3 Nevertheless, raising HDL levels in mice via overexpression of human apoA1 (apolipoprotein A1) has consistently reduced atherosclerosis in mouse models. 4, 5 The antiatherogenic property of HDL is partly attributed to its role in reverse cholesterol transport. This pathway starts with apoA1 interacting with cellular ABCA1 (ATP-binding cassette protein A1) to assemble cellular free cholesterol and phospholipids to form nascent HDL (nHDL). We have shown that ABCA1 mediates the unfolding of apoA1's N-terminal helical hairpin 6 and proposed a model for the mechanism of ABCA1-mediated nHDL assembly. 7 ABCA1 mediates the outward translocation (floppase activity) of 2 phospholipid species, phosphatidylserine (PS) 8 and phosphatidylinositol 4,5-bisphosphate (PIP2), and these 2 floppase activities are independent of each other and mediated by different extracellular loops of the ABCA1 protein. 9 The PIP2 floppase activity of ABCA1 is both necessary and sufficient to promote the cellular binding of apoA1. 9 Once bound to ABCA1-expressing cells, ABCA1 then mediates the partial unfolding of the N terminus of apoA1. The unfolded apoA1 is subject to spontaneous lipidation, which resolves in the release of nHDL from the cell. 6 V-ATPase (vacuolar ATPase) resides within many intracellular compartments, including the endosomal/lysosomal membrane where it pumps protons into the organelle to lower vesicle pH. 10 V-ATPase has also been identified on the plasma membrane in osteoclasts, renal intercalated cells, and macrophages. [11] [12] [13] [14] V-ATPase is composed of a peripheral cytoplasmic domain (V 1 , 8 subunits), which is responsible for ATP hydrolysis, and an integral membrane domain (V 0 , 6 subunits), which is involved in proton translocation across the membrane. Fukuda et al 15 demonstrated that lipid-free apoA1 undergoes a conformational change exposing its hydrophobic regions under acidic pH, leading to the acceleration of reconstituted HDL (rHDL) formation from egg phosphatidycholine (PC):PS liposomes. Others have shown that incubation of plasma HDL at acidic pH enhances its cholesterol efflux capacity because of HDL remodeling and the release of lipid-poor/lipid-free apoA1. 16 Thus, we postulated that the acidifying ability of V-ATPase may play a role in the ABCA1-mediated apoA1 unfolding and lipidation.
In our current study, we showed that cholesterol efflux to apoA1 is blocked by V-ATPase inhibitors in ABCA1 stably transfected baby hamster kidney (BHK) and RAW264.7 cells and also inhibited by siRNA knockdown of ATP6V 0 C in RAW264.7 cells. We demonstrated that ABCA1 does not alter total cellular levels of V-ATPase, but interestingly, ABCA1 increased the cell surface levels of the V 0 A1 and V 1 E1 subunits of V-ATPase. Using a fluorescent ratiometric apoA1 pH indicator by flow cytometry, we found that incubation of the apoA1 pH indicator with ABCA1-expressing cells at 37°C led to apoA1 acidification, and V-ATPase inhibitor dose-dependently eliminated the apoA1 acidification in the ABCA1-expressing cells. However, we did not detect extracellular acidification mediated by ABCA1 induction. We found that unfolding of apoA1 tertiary structure is facilitated at acidic pH, as is membrane fluidity in PC:PS liposomes. Therefore, our data support a model that ABCA1 brings V-ATPase to the plasma membrane where the V-ATPase can promote membrane remodeling and cellular apoA1 acidification and unfolding, which are required for ABCA1-mediated nHDL biogenesis and cholesterol efflux.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Cholesterol Efflux
Cholesterol efflux experiments were performed according to established procedures 17 with minor modification. On day 1, BHK cells were plated onto a 24-well plate at a density of 150 000 cells per well. On day 2, the cells were labeled with 3H cholesterol. On day 3, the cells were treated with 10 nmol/L mifepristone for 16 hours to induce ABCA1 expression. 18 On day 4, the cells were washed and chased for 4 hours in serum-free medium and the presence or absence of 5 μg/mL human apoA1. The radioactivity in the chase media was determined after brief centrifugation to pellet debris. Radioactivity in the cells was determined by extraction in hexane:isopropanol (3:2) with the solvent evaporated in a scintillation vial before counting. The percentage cholesterol efflux was calculated as 100×(medium dpm)/(medium dpm+cell dpm). ApoA1 efflux from RAW264.7 cells was performed as previously described using a 16-hour treatment with 0.3 mmol/L 8-Br-cAMP to induce ABCA1. 
Quantitative Real-Time Polymerase Chain Reaction
Detailed methods are found in the online-only Data Supplement.
Detection of Lysosomal/Endosomal Acidification
BHK cells or RAW cells transfected with ATP6V 0 C or scramble siRNA were incubated with fluorescein and tetramethylrhodamine (TMR) dual-labeled dextran (D1951; Thermo Fisher) for 16 hours and chased in phenol red free medium for 1 hour, in the presence or absence of bafilomycin A1 (sc-201550A; Santa Cruz). Cellular fluorescein and TMR intensity were measured by flow cytometry. The fluorescein/TMR ratio of every cell was calculated to plot frequency histograms displaying the lysosomal/endosomal acidification range for ≈10 000 cells for each condition.
Total and Cell Surface V-ATPase Detection and Quantification
BHK cells were cell surface biotinylated, and cell surface proteins were pulled down using streptavidin beads. V-ATPase subunits were detected by Western blot. Detailed methods are found in the online-only Data Supplement. All antibody sources and concentrations are listed in the Major Resources Tables in the online-only Data Supplement.
Cellular V-ATPase Localization
BHK cells were incubated in the absence or presence of 10 nmol/L mifepristone to induce ABCA1 expression. For cellular V-ATPase localization, BHK cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Cells were stained with 1 μg/mL rabbit polyclonal antibody raised against V-ATPase V 0 A1 antibody (sc-28801; Santa Cruz) at room temperature for 1 hour and probed with 2 μg/mL Alexa568-conjugated goat anti-rabbit secondary antibody (A-11036; Thermo Fisher). All images were captured using an Olympus IX51 inverted epifluorescent microscope with a Q-Image EXi Aqua camera and Olympus cellSens 1.7 software.
ApoA1 pH Indicator
To make the apoA1 pH indicator, human plasma apoA1 was doubly labeled on free amines with fluorescein isothiocyanate (FITC), whose fluorescence decreases in an acidic environment, and Alexa647. Human apoA1 was dissolved in 0. 
Measuring Extracellular Acidification Using the Seahorse XF24 Analyzer
ApoA1 Guanidine Denaturation
ApoA1 was prepared at 50 μg/mL in increasing concentration of guanidine hydrochloride in sodium phosphate buffer (pH 5 and 7.5). The tryptophan fluorescence spectra of each sample was measured using a SpectraMax M2e plate reader with an excitation fixed at 290 nm and emission from 300 to 450 nm at 23°C. The wavelength of maximum fluorescence was determined, which is dependent on the apoA1 tryptophan environment, with a red shift observed as tryptophan goes from a hydrophobic to an aqueous environment.
Liposome Clearance Assay
Surface Plasmon Resonance to Assess apoA1 Binding to Large Unilamellar Vesicles
Egg PC:palmitoyloleoylphosphatidyserine (POPS; 8:2 mole ratio) large unilamellar vesicles (LUVs) containing 0.1% phosphatidylethanolamine-biotin in acetate buffer (pH 4.5) and phosphate buffer (pH 7.1) were prepared as described above. Surface plasmon resonance experiments were performed at 37°C on a Biacore 3000 using the streptavidin conjugated Sensor Chip SA (BR-1000-32). LUVs containing 0.1% biotinylated phosphatidylethanolamine at a concentration of 30 μg/mL were bound to the streptavidin chip. Human apoA1 (25 μg/mL) at pH 7.1 or pH 4.5 was injected as indicated onto the sensor to probe the mass change on the sensor.
Diphenylhexatriene Fluorescence Anistropy
Egg PC:POPS:diphenylhexatriene (DPH; 8:2:0.2 mole ratio; Sigma) LUVs were prepared as described above. DPH anisotropy was used to compare membrane fluidity as described previously. 19 Polarized emission of the DPH-labeled LUVs and apoA1 lipid complexes was measured at pH 7.1 and pH 4.5 over various temperatures using Polaroid filters in a Perkin-Elmer LS50B. DPH fluorescence anisotropy, r, was measured with excitation at 357 nm and emission at 427 nm, using 10 nm bandwidths, and calculated using software built into the Perkin-Elmer LS50B spectrophotometer.
Statistics
Data are shown as mean±SD. Comparisons of 2 groups were performed by a 2-tailed t test, and comparisons of ≥3 groups were performed by ANOVA with Tukey post-test. All statistics were performed using Prism V7.03 software (GraphPad).
Results

Inhibition of V-ATPase Blocks ABCA1-Mediated Cholesterol Efflux
Bafilomycin A1 and concanamycin A are highly specific V-ATPase inhibitors that raise lysosomal pH and inhibit lysosome function. To determine whether V-ATPase is required in the ABCA1-mediated cholesterol efflux to apoA1, we performed cholesterol efflux assay in the presence of bafilomycin A1 in BHK cells. Human ABCA1 expression in stably transfected BHK cells was induced by mifepristone and as described previously. 18 Cholesterol efflux to apoA1 was highly induced in these cells on ABCA1 induction ( Figure 1A ). We observed that a16-hour pretreatment with bafilomycin A1 at 5 to 15 nmol/L concentrations greatly inhibited ABCA1-mediated cholesterol efflux to apoA1 ( Figure 1A ; P<0.0001 for different doses by ANOVA post-test, efflux inhibited by 63% at 15 nmol/L), but we chose not to use this condition in our following experiments to avoid secondary effects in response to prolonged lysosomal inhibition, such as induction of TFEB and lysosome biogenesis. 20 We found that a 1-hour pretreatment with 10 nmol/L or 10 μM bafilomycin A1 dose-dependently inhibited ABCA1-mediated cholesterol efflux to apoA1 by 28% and 88%, respectively ( Figure 1B To further confirm the role of V-ATPase in ABCA1-mediated cholesterol efflux, we performed siRNA knockdown of ATP6V 0 C, which is the bafilomycin A1 binding subunit of V-ATPase, in RAW264.7 cells (BHK cells lack commercially available siRNA). Using quantitative real-time polymerase chain reaction analysis with β-actin mRNA expression as an internal standard, we showed that ATP6V 0 C mRNA expression was significantly reduced by 72% after nucleofection with ATP6V 0 C siRNA ( Figure 1C ; P<0.0001), and ABCA1-mediated cholesterol efflux to apoA1 was inhibited by 44% ( Figure 1D ; P<0.0001 by ANOVA post-test). We replicated this inhibitory effect of ATP6V 0 C knockdown on cholesterol efflux with ATP6V 0 C siRNA tranfected by TransIT-TKO method ( Figure ID and IE in the online-only Data Supplement). Therefore, both pharmacological inhibition and gene silencing of V-ATPase are able to inhibit ABCA1-mediated cholesterol efflux to apoA1. The mitochondrial F-ATPase inhibitors, IF1 and piceatannol, did not inhibit ABCA1-mediated cholesterol efflux to apoA1 ( Figure IIA and IIB in the online-only Data Supplement), further indicating the unique role of the lysosomal V-ATPase in ABCA1-mediated cholesterol efflux.
We then measured the effect of a 1-hour treatment of 10 nmol/L and 10 μM bafilomycin A1 on lysosomal/endosomal pH after the uptake of a commercially available fluorescein and TMR dual-labeled dextran. As pH increases in the intracellular vesicles because of bafilomycin A1 treatment, the fluorescein/TMR emission ratio increases. We measured cellular fluorescein and TMR intensity by flow cytometry and plotted the frequency distribution of the fluorescein/TMR ratio in ≈10 000 cells. This assay demonstrated incomplete inhibition of lysosome acidification by 10 nmol/L bafilomycin A1, compared with 10 μM bafilomycin A1 ( Figure 1E ), thus justifying the use of the higher dose in our study. We also performed the same assay in RAW cells after ATP6V 0 C siRNA knockdown. ATP6V 0 C knockdown increased lysosomal/endosomal pH attaining approximately half of the effect of 10 μM bafilomycin A1 ( Figure 1F ), which goes along with its less-prominent inhibitory effect on cholesterol efflux ( Figure 1D) .
To determine the effect of inhibiting lysosomal proteolysis on ABCA1-dependent cholesterol efflux, BHK cells were incubated with the lysosomal protease inhibitor leupeptin, and we found no effect on cholesterol efflux to apoA1 ( Figure III in the online-only Data Supplement). To determine whether increasing lysosomal pH without V-ATPase inhibition also inhibited ABCA1-mediated cholesterol efflux, we pretreated cell with the weak base ammonium chloride that also increases lysosomal pH, and we observed a small 10.7% decrease in cholesterol efflux to apoA1 ( Figure IVA in the online-only Data Supplement). Using the dual-labeled dextran assay, we found that 20 mmol/L ammonium chloride and 10 μM bafilomycin A1 both resulted in the same increase in lysosomal pH ( Figure  IVB in the online-only Data Supplement). Thus bafilomycin A1 and ammonium chloride increased endosomal/lysosomal pH to the same extent, whereas only the V-ATPase inhibitor strongly decreased cholesterol efflux to apoA1.
ABCA1 Increases Cell Surface V-ATPase
Because V-ATPase inhibitors blocked ABCA1-mediated cholesterol efflux, we measured whether ABCA1 induction altered the level of V-ATPase. Western blots of control and ABCA1-induced cells demonstrated that the total cellular levels of the V 0 A1 and V 1 E1 subunits were not changed by ABCA1 induction; however, the cell surface levels of the V 0 A1 and V 1 E1subunits, detected by cell surface biotinylation, were increased by ABCA1 induction (Figure 2A ; entire blots available in Figure VA and VB in the online-only Data Supplement). We blotted GAPDH in the biotinylation assay as whole cell protein control. The loading was similar in 4 lanes of whole cell lysate, and there was no contamination from intracellular protein GAPDH in 4 lanes of cell surface lysate ( Figure VI in the online-only Data Supplement). The increase in cell surface V-ATPase was further confirmed by flow cytometry using fixed but unpermeabilized cells stained for V 0 A1, where ABCA1 induction led to a 59% increase in cell surface V-ATPase (P=0.004; Figure 2B ). Immunofluorescence microscopy of permeabilized cells stained for V 0 A1 also confirmed that cell surface V-ATPase was increased on ABCA1 induction ( Figure 2C) . Furthermore, the ABCA1-mediated increase in cell surface V-ATPase was not affected by bafilomycin A1 treatment ( Figure 2C) . Therefore, ABCA1 recruits V-ATPase to the cell surface.
ABCA1 Induces apoA1 Acidification Mediated by V-ATPase
To investigate whether apoA1 is acidified at the presence of ABCA1 expression, we designed a fluorescent ratiometric apoA1 pH indicator using the pH-sensitive and insensitive dyes FITC and Alexa647, respectively. This apoA1 pH indicator was validated in solution assay showing that FITC/Alexa647 emission ratio decreased as the pH goes down, with an EC 50 of pH 6.6 ( Figure 3A) . Furthermore, the FITC/Alexa647 labeled apoA1 retained full cholesterol acceptor activity compared with unmodified apoA1 (Figure 3B ). Human ABCA1 expression induced by mifepristone in BHK cells led to increased apoA1 uptake, and the nonspecific apoA1 uptake in cells without ABCA1 induction is also detectable and sufficient for use of our ratiometric apoA1 pH indicator ( Figure 3C ). We measured cellular FITC and Alexa647 intensity by flow cytometry and plotted the frequency distribution of the FITC/Alexa647 ratio in ≈10 000 cells. Incubation of the apoA1 pH indicator with ABCA1-induced versus noninduced BHK cells for 45 minutes at 37°C led to a large shift of FITC/Alexa647 ratio to the left, indicating a lower pH of the apoA1 indicator in ABCA1-expressing cells ( Figure 3D) . We replicated the result in RAW264. 7 , and separated from the cellular lysate by streptavidin pull-down. Total and cell surface V-ATPase subunits were detected by Western blot analysis. B, ABCA1-induced and noninduced BHK cells were fixed without permeabilization and were stained with antibody against V-ATPase V 0 A1. Flow cytometry was used to measure cell surface V-ATPase (n=3; mean±SD; P=0.0004). C, ABCA1-induced and noninduced BHK cells were pretreated ±10 μM bafilomycin A1 for 1 h, fixed, permeabilized, and stained with antibody against V-ATPase V 0 A1 followed by epifluorescent microscopy (40× objective) for V-ATPase (red) and DAPI (blue). ABCA1 expression increased the level of V-ATPase on the cell surface (white arrows) independent of bafilomycin A1 treatment.
Data Supplement). The acidification of cell-associated apoA1 is expected based on prior work showing that apoA1 is taken up by endosomes, in an ABCA1-dependent manner, with a fraction delivered to lysosomes and a fraction being resecreted by retroendocytosis. [22] [23] [24] [25] [26] We repeated the above apoA1 pH indicator studies in cells pretreated for 1 hour with 10 nmol/L or 10 μM bafilomycin A1. Bafilomycin A1 of 10 nmol/L partially blocked the ABCA1-induced apoA1 acidification ( Figure 4A ), whereas 10 μM bafilomycin A1 completely blocked the ABCA1-induced apoA1 acidification ( Figure 4B ). Treatment by 10 μM bafilomycin A1 did not inhibit the uptake of Alexa647-labeled apoA1, as assed by flow cytometry ( Figure 4C ). We also found that a 16-hour pretreatment with 10 nmol/L bafilomycin A1 inhibited most of the ABCA1-induced apoA1 acidification ( Figure VIII in the online-only Data Supplement). In addition, bafilomycin A1 treatment of the BHK cells did not block ABCA1-dependent cholesterol efflux to the weak detergent sodium taurocholate (2 mmol/L; Figure IX in the online-only Data Supplement). Thus, the ABCA1-dependent apoA1 acidification requires V-ATPase activity that mediates apoA1 acidification.
ABCA1 Does Not Increase Extracellular Proton Release
V-ATPase normally pumps protons into the endosome/lysosome to lower vesicle pH. However, when the endosome/ lysosome fuses with the plasma membrane, V 1 domain will be on the cytoplasmic side of the membrane, and protons would be pumped from the cytoplasm to the extracellular environment. 27 Because ABCA1 induces apoA1 acidification and increases cell surface V-ATPase, we examined whether ABCA1 increases V-ATPase activity to pump protons out of cells. Using an XF24 Seahorse Analyzer, we measured the extracellular acidification rate (ECAR), which detects acid released by the cells into the medium. Glycolysis and lactic acid release is the major contributor to ECAR; therefore, we used 2-deoxyglucose to inhibit the rate-limiting enzyme of glycolysis and oxamate to inhibit nonglycolytic pyruvate conversion to lactic acid. We examined ECAR in BHK cells during a time course and demonstrated that inhibition of glycolysis decreased ECAR as expected ( Figure 4D ). However, there was no difference in ECAR between ABCA1-induced and noninduced BHK cells. After adding the V-ATPase inhibitor bafilomycin A1 to cells, we did not observe a further decrease of ECAR but a slow increase over time. Similar results were obtained with the V-ATPase inhibitor concanamycin A (Figure X in the online-only Data Supplement). Thus, despite the increase in cell surface V-ATPase in ABCA1-expressing cells, there was no detectable increase in acid released from the cells to the media, nor was V-ATPase activity responsible for the baseline acid release from these cells. 
Acidic pH-Dependent apoA1 Unfolding and rHDL Formation
To directly observe whether acidic pH facilitates apoA1 unfolding, we performed an apoA1 guanidine denaturation study. ApoA1 has 4 tryptophan residues, which are largely protected from the aqueous environment, and aqueous exposure of the tryptophan residues induced by increasing concentrations of guanidine can be assessed by a red shift in the peak fluorescent emission wavelength. As the guanidine concentration was increased from 0 to 3 M at neutral pH (pH 7.5), apoA1 exhibited a wavelength of maximum fluorescence shift from 352.2 to 367.6 nm, with an EC 50 of 0.94 M guanidine ( Figure 5A ). On repeating this study at pH 5.0, we observed a similar wavelength of maximum fluorescence shift of apoA1 from 351.5 to 368.0 nm. However, the EC 50 at pH 5.0 was 0.75 M guanidine, showing that apoA1 unfolding in guanidine was facilitated at acidic pH. rHDL is easily formed from LUVs made up of the nonphysiological phospholipid dimyristoylphosphatidylcholine on incubation with lipid-free apoA1 at 21°C; however, LUVs made from physiological palmitoyloleoylphosphatidylcholine or egg PC are not solubilized by apoA1 to form rHDL. 15, 28 Fukuda et al 15 demonstrated that LUVs made with egg PC or PC:PS (8:2) could be solubilized by apoA1 at 37°C but only at low pH. We reproduced this finding using LUVs made of egg PC:POPS (8:2 mole ratio), showing solubilization by apoA1 at pH <6.0, in a pH-dependent fashion ( Figure 5B ). Furthermore, we confirmed this finding by surface plasmon resonance to follow the interaction of injected apoA1 and immobilized egg PC:POPS (8:2 mole ratio) LUVs. At pH 7.1, apoA1 did not exhibit binding to LUVs and did not solubilize the LUVs, but at pH 4.5, injected apoA1 led to a transient rise in apparent mass on the chip, as the apoA1 bound to LUVs, then led to a steady-state decrease in total mass on the chip presumably because of the formation and release of rHDL ( Figure 5C ). In addition, we also discovered that acidic pH directly increased lipid disorder in the egg PC:POPS LUVs, as measured by DPH anisotropy, particularly at physiological temperatures ( Figure 5D ). Thus, lowered pH destabilized the tertiary structure of apoA1, increased lipid disorder in the LUVs, and led to rHDL formation from physiological liposomes.
Discussion
The ABC (ATP-binding cassette) gene family is found in organisms ranging from bacteria to humans and includes hundreds of different proteins, many acting as transporters. Prior examples of various ABC proteins in maintaining low pH in organelles have been shown in several species. For example, in Dictyostelium, the ABC transporter mdrA1/mdrA2 is required for the acidification of endosomes. 29 The Caenorhabditis elegans ABC transporter pgp-2 plays a direct role in regulating intestinal lysosome biogenesis and acidification. 30, 31 The Plasmodium faciparum ABC transporter Pgh1 regulates acidification of vacuoles, and Pgh1 is speculated to function as a chloride channel or regulator of V-ATPase. 32 Here, we demonstrated that ABCA1 recruits V-ATPase to the cell surface, without changing the total levels of V-ATPase and that inhibition of V-ATPase greatly impairs ABCA1-mediated cholesterol efflux. It is possible that ABCA1-mediated increased exocytosis, decreased endocytosis, and increased endosome recycling could be a mechanism responsible for increased V-ATPase level on the plasma membrane. ABCA1 is a large ABC gene family protein with 12 transmembrane domains, 2 large extracellular domains, and 2 ATP-binding domains. We previously demonstrated that ABCA1 is a PIP2 floppase and that cell surface PIP2 is required for cellular apoA1 binding. 9 The previously demonstrated PS floppase activity of ABCA1 is inhibited by mutations in the first large extracellular domain, 33 ,34 whereas we showed that mutations in the second large extracellular domain inhibit PIP2 floppase and apoA1 cellular binding. 9 Although bafilomycin A1 inhibited ABCA1-mediated cholesterol efflux to apoA1, ABCA1-dependent cholesterol efflux to sodium taurocholate was not inhibited by bafilomycin A1 treatment. Because ABCA1-dependent efflux to sodium taurocholate requires the PS floppase activity of ABCA1 (efflux to sodium taurocholate is disrupted by the same mutations in the first large extracellular domain of ABCA1), 6, 34 we can infer that bafilomycin A1 did not inhibit the PS floppase activity of ABCA1. In addition, because apoA1 cellular binding was not altered by bafilomycin A1, we can infer that the PIP2 floppase activity of ABCA1 was not inhibited by bafilomycin A1 treatment.
V-ATPase, in addition to residing in endosomes/lysosomes, has also been found on the plasma membrane in mammalian cells. [11] [12] [13] [14] V-ATPase on the plasma membrane of osteoclasts forms an acidic extracellular compartment to promote bone reabsorption, and mice deficient in Tcirg1 (gene encoding V-ATPase subunit V 0 A3, previously called Atp6i) exhibit severe osteopetrosis because of loss of extracellular acidification and impaired bone remodeling. 11 Maxfield et al 14 have shown that cell surface V-ATPase in macrophages can create a transiently sealed acidic extracellular hydrolytic compartment that promotes the digestion of aggregated low-density lipoprotein. Thus, there is precedence for the regulated activity of V-ATPase on the plasma membrane. In our current study, ABCA1 induction in BHK cells did not lead to a decrease in the extracellular pH that we could detect using the Seahorse ECAR assay, perhaps this could be because of lack of sufficient sensitivity of this assay. The lack of detectable extracellular acidification could also be because of a passive diffusion of secreted protons back across the plasma membrane down their electrochemical gradient into the cell 35 or via an active transporter, such as the potassium-proton antiporter. 36 Alternatively, this situation could be similar to what Maxfield observed with the formation of a transiently sealed compartment on the plasma membrane so that the V-ATPase-extruded protons did not reach the bulk extracellular medium.
ABCA1 resides not only on the plasma membrane but also in intracellular vesicles, including early/late endosomes, which transfer ABCA1 to and from the plasma membrane. 23 Moreover, intracellular apoA1 traffics in the ABCA1-containing vesicles to the perinuclear region and back to the cell surface. 24 We previously showed that apoA1 could be taken up by endocytosis into macrophages, in an ABCA1-dependent manner, and resecreted as nHDL, and that blocking endocytosis impairs lipid efflux to apoA1. 22 Others have shown that intracellular pools of cholesterol constituted the major cholesterol source for ABCA1-mediated cholesterol efflux to apoA1. 37 Genest demonstrated that resecretion of apoA1 from intracellular compartments is faster than from plasma membrane. 25 In addition, ABCA1-mediated lipid efflux has delayed kinetics and is abolished at room temperature, results that are also consistent with a role for endocytosis and vesicular trafficking in this process. 38 Interestingly, when ABCA1 and apoA1 internalization is blocked, cholesterol efflux from cells that have accumulated intracellular cholesterol is decreased, whereas efflux from cells without intracellular cholesterol accumulation is increased. 26 Thus, the retroendocytosis pathway may contribute to HDL formation by macrophages when excess cholesterol has accumulated inside the cell. Since ABCA1, apoA1, and V-ATPase are all found together in endosomes, it is possible that V-ATPase acidification of the endosome lumen may facilitate the lipidation of apoA1 and nHDL generation. However, it is clear that nHDL assembly and lipid efflux can also occur on the plasma membrane. 39 In macrophages that were not cholesterol loaded, it has been calculated that the amount of intact apoA1 resecreted from the cells is not sufficient to account for the HDL produced by the cholesterol efflux reaction. 26 In this scenario, increased V-ATPase on the plasma membrane in ABCA1-expressing cells may facilitate apoA1-mediated efflux on the cell surface. Our current study found that ammonium chloride increased lysosomal pH but did not inhibit ABCA1-mediated cholesterol efflux. This implicates that plasma membrane V-ATPase activity was required for ABCA1-mediated cholesterol efflux. Although, early endosomal acidification may not be abrogated by ammonium chloride, and V-ATPase activity in this compartment may also increase ABCA1-mediated cholesterol efflux.
The V-ATPase has a similar structure to the mitochondrial F 0 F 1 ATP synthase, and both use molecular motors to transport protons linked to ATP hydrolysis or synthesis. Interestingly, the F 1 β-chain subunit (ATP5F1B gene), and possibly other subunits, is expressed ectopically on the surface of hepatocytes and endothelial cells, where it can serve as a receptor for apoA1 to mediate HDL uptake or transcytosis. 40 ,41 siRNA Figure 6 . The role of V-ATPase (vacuolar ATPase) in the ABCA1 (ATP-binding cassette protein A1)-mediated nascent HDL (high-density lipoprotein; nHDL) biogenesis. ABCA1 expression recruits V-ATPase to the plasma membrane, which can lead to apoA1 (apolipoprotein A1) acidification to promote its N-terminal unfolding, as well as membrane acidification to increase lipid fluidity. N-terminal unfolded apoA1 is able to spontaneously interact with membrane lipids to generate and release nHDL from the cell. The dashed line indicates that in some cells, such as cholesterol loaded macrophages, apoA1 acidification and nHDL formation may occur in endosomes, followed by retroendocytosis and the release of the nHDL. V-ATPase inhibition (bafilomycin A1) impairs nHDL biogenesis without impeding apoA1 binding/uptake.
knockdown of the β-chain or treatment with an ATP synthase inhibitory peptide IF1 reduced cell binding of apoA1 in endothelial cells. 41 The murine F 1 β-chain amino acid sequence has 20.5% identity with the murine V-ATPase V 1 B subunit. It is possible that the V 1 B subunit of the V-ATPase could also promote apoA1 binding, and the close physical interaction between apoA1 and V-ATPase could facilitate apoA1 acidification and lipidation. However, we found that treatment with F-ATPase inhibitors did not decrease ABCA1-mediated cholesterol efflux to apoA1.
Mechanistically, the requirement for V-ATPase activity for ABCA-mediated cholesterol efflux is probably related to the effect of low pH on promoting the unfolding of apoA1 to expose its hydrophobic residues ( Figure 5A ), as well as promoting phospholipid bilayer fluidity ( Figure 5D ), both of which can promote apoA1 insertion into cellular membranes, membrane microsolubilization, and the release of nHDL. In addition, we confirmed here ( Figure 5B ) the previously described effect of acidic pH to accelerate liposome clearance and rHDL formation in cell-free studies using liposomes made from physiological phospholipids. 15 It has also been observed that treatment of HDL 2 and HDL 3 subfractions at acidic pH leads to HDL remodeling, the release of lipid-free apoA1, and HDL remnant fusion. 16 We have shown that ABCA1 independently flops PS and PIP2 to the outer leaflet of the plasma membrane, with the former promoting detergent sensitivity to the plasma membrane and the latter mediating apoA1 binding. 6, 9 Our current study, modeled in Figure 6 , shows that ABCA1 also recruits V-ATPase to the plasma membrane. V-ATPase proton pumping can acidify apoA1 on the plasma membrane or in early endosomes. Acidification facilitates the partial unfolding of apoA1 and increased membrane fluidity, and the unfolded apoA1 is able to spontaneously insert into the membrane, which resolves in the release of nHDL directly from the plasma membrane or into the endosome lumen, from which it can be released by retroendocytosis. Although we have no direct proof that apoA1 acidification and unfolding are required for nHDL biogenesis via ABCA1, inhibiting V-ATPase activity impaired apoA1 acidification and nHLD biogenesis, and inhibiting V-ATPase expression also impaired nHDL biogenesis. Along with our in vitro data showing that apoA1 acidification increased apoA1 unfolding and liposome solubilization, the most parsimonious explanation for our observations is consistent with our model.
In conclusion, we showed that ABCA1-mediated apoA1 lipidation requires V-ATPase activity and that ABCA1 recruits V-ATPase to the cell surface. Together, these findings increase our insight into the mechanism by which ABCA1 mediates apoA1 lipidation and suggest that modulation of V-ATPase and apoA1 acidification may serve as new targets for increasing cholesterol efflux activity.
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